NeoPredics Announces Prof. Stefan Verlohren as Chairman of Medical and Scientific Advisory Board

FORT LAUDERDALE, FLORIDA / ACCESSWIRE / January 2, 2025 / NeoPredics AG Switzerland, together with its subsidiaries NeoPredics AG Germany and NeoPredics USA Inc., a leader in predictive analytics and clinical decision support for maternal and neonatal health, is proud to announce that Prof. Stefan Verlohren will join the company as Chairman of the Medical and Scientific Advisory Board, effective January 1, 2025.

Prof. Verlohren is a highly distinguished Professor of Obstetrics and the Chairman and Director of the Department of Obstetrics and Fetal Medicine at University Medical Center Hamburg-Eppendorf (UKE), Germany. With over two decades of experience in maternal-fetal medicine and an extensive background in clinical innovation, he has dedicated his career to advancing care for women and newborns.

Thorsten Waloschek, CEO of NeoPredics, shared his enthusiasm about the appointment:

“Prof. Verlohren’s leadership and expertise in maternal-fetal medicine align perfectly with NeoPredics’ mission to transform outcomes for women and newborns. His guidance will strengthen our commitment to predictive technologies that ensure timely and precise interventions in critical moments of care.”

Prof. Verlohren’s addition to NeoPredics’ advisory board reflects the company’s strategy to partner with global leaders in healthcare to advance NeoPredics’ vision. His experience with innovative projects, such as the PreFree initiative, and his significant contributions to the field of preeclampsia and hypertensive pregnancy disorders further solidify NeoPredics’ position at the forefront of maternal and neonatal health solutions.

NeoPredics remains committed to redefining healthcare for women and children through cutting-edge predictive algorithms. The addition of Prof. Verlohren to the medical team of the two founders Prof. Sven Wellmann and Prof. Marc Pfister, is a significant milestone in this journey.

Contact Information

Lia Butler
Director of Sales & Marketing, US
lia.butler@neopredics.com
6092736911

SOURCE: NeoPredics

View the original press release on accesswire.com

Staff

Recent Posts

SHOWCASING TOMORROW’S INNOVATORS: LG NOVA RETURNS TO CES 2025

LG NOVA Pushes Forward the Future of Collaboration and Innovation Across Healthtech, AI and Cleantech…

2 minutes ago

AEON Biopharma, Inc. Announces Launch of Proposed Public Offering

IRVINE, Calif., Jan. 03, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”)…

9 hours ago

Oculis Publishes Notification of Major Changes in Voting Rights

ZUG, Switzerland, Jan. 04, 2025 (GLOBE NEWSWIRE) -- Attached is a Notification of Major Changes…

9 hours ago

ARCPOINT CLOSES SALE OF OWNERSHIP STAKE IN NON-CORE ASSET

Greenville, South Carolina , Jan. 03, 2025 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV: ARC) (the…

9 hours ago

Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Carlsbad, CA, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (Nasdaq: PALI) (“Palisade”, “Palisade…

9 hours ago

PharmaTher Announces Grant of Stock Options

TORONTO, Jan. 03, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB:…

9 hours ago